Andrew Reardon
CLO & Secretary. Files against LGND. Everything below is filed with the SEC within two business days of the trade. Filed as Reardon Andrew.
Every reported line
Purchases, sales, grants, option exercises and shares withheld for tax.
| Company | Action | Value |
|---|---|---|
| LGNDLigand Pharmaceuticals Inc2026-10-02 | Sale10b5-1 plan | $123.7K |
| LGNDLigand Pharmaceuticals Inc2026-10-02 | Sale10b5-1 plan | $467.4K |
| LGNDLigand Pharmaceuticals Inc2026-10-02 | Sale10b5-1 plan | $599.8K |
| LGNDLigand Pharmaceuticals Inc2026-10-02 | Sale10b5-1 plan | $252K |
| LGNDLigand Pharmaceuticals Inc2026-10-02 | Option exercise10b5-1 plan | $17.8K |
| LGNDLigand Pharmaceuticals Inc2026-10-02 | Option exercisederivative10b5-1 plan | — |
| LGNDLigand Pharmaceuticals Inc2026-10-02 | Sale10b5-1 plan | $5.2K |
| LGNDLigand Pharmaceuticals Inc2026-10-02 | Sale10b5-1 plan | $72.2K |
| LGNDLigand Pharmaceuticals Inc2026-09-03 | Sale10b5-1 plan | $85.2K |
| LGNDLigand Pharmaceuticals Inc2026-09-03 | Sale10b5-1 plan | $513.3K |
| LGNDLigand Pharmaceuticals Inc2026-09-03 | Sale10b5-1 plan | $605.6K |
| LGNDLigand Pharmaceuticals Inc2026-09-03 | Sale10b5-1 plan | $110.7K |
| LGNDLigand Pharmaceuticals Inc2026-09-03 | Sale10b5-1 plan | $115.6K |
| LGNDLigand Pharmaceuticals Inc2026-08-03 | Sale10b5-1 plan | $58.1K |
| LGNDLigand Pharmaceuticals Inc2026-08-03 | Sale10b5-1 plan | $289.1K |
| LGNDLigand Pharmaceuticals Inc2026-08-03 | Sale10b5-1 plan | $119.8K |
| LGNDLigand Pharmaceuticals Inc2026-08-03 | Option exercisederivative10b5-1 plan | — |
| LGNDLigand Pharmaceuticals Inc2026-08-03 | Sale10b5-1 plan | $145.8K |
| LGNDLigand Pharmaceuticals Inc2026-08-03 | Sale10b5-1 plan | $102.8K |
| LGNDLigand Pharmaceuticals Inc2026-08-03 | Sale10b5-1 plan | $349.4K |
| LGNDLigand Pharmaceuticals Inc2026-08-03 | Sale10b5-1 plan | $29.8K |
| LGNDLigand Pharmaceuticals Inc2026-08-03 | Option exercise10b5-1 plan | $261.4K |
| LGNDLigand Pharmaceuticals Inc2026-08-03 | Sale10b5-1 plan | $296K |
| LGNDLigand Pharmaceuticals Inc2026-08-03 | Sale10b5-1 plan | $44.9K |
| LGNDLigand Pharmaceuticals Inc2026-08-03 | Sale10b5-1 plan | $9.4K |
| LGNDLigand Pharmaceuticals Inc2026-07-01 | Sale10b5-1 plan | $31.5K |
| LGNDLigand Pharmaceuticals Inc2026-07-01 | Sale10b5-1 plan | $190.3K |
| LGNDLigand Pharmaceuticals Inc2026-07-01 | Option exercisederivative10b5-1 plan | — |
| LGNDLigand Pharmaceuticals Inc2026-07-01 | Sale10b5-1 plan | $284.2K |
| LGNDLigand Pharmaceuticals Inc2026-07-01 | Option exercise10b5-1 plan | $261.4K |
| LGNDLigand Pharmaceuticals Inc2026-07-01 | Sale10b5-1 plan | $122.4K |
| LGNDLigand Pharmaceuticals Inc2026-07-01 | Sale10b5-1 plan | $32.3K |
| LGNDLigand Pharmaceuticals Inc2026-07-01 | Sale10b5-1 plan | $348.8K |
| LGNDLigand Pharmaceuticals Inc2026-07-01 | Sale10b5-1 plan | $337.6K |
| LGNDLigand Pharmaceuticals Inc2026-07-01 | Sale10b5-1 plan | $219.4K |
| LGNDLigand Pharmaceuticals Inc2026-06-30 | J10b5-1 plan | $21.2K |
Source: SEC Form 4 and Form 144 filings, via EDGAR. Form 144 carries no filer identifier, so those notices are matched to this page by name alone. Value is shares times the reported price, and is blank where the filing priced the transaction at zero — a grant costs its recipient nothing. Insiders sell for reasons that have nothing to do with the company, which is why a sale is not read as a signal on its own.
Follow Andrew Reardon by email
Andrew Reardon's new Form 4 trades, with the rest of the week's filings. One email a week, free.
Unsubscribe with one click from any email.